Tennessee Center for Clinical Trials

Tullahoma, Tennessee 37388

5 studies enrolling now · 29 studies all time

What they study most

Acute Decompensated Heart Failure, Angina Pectoris, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation, Atrial Flutter, Cardiovascular Disease, Cardiovascular Diseases, Chronic Heart Failure, Chronic Kidney Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities, Dilated Cardiomyopathy

Studies at this site

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction — Recruiting now
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) — Recruiting now
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
SELUTION4BTK Trial — Recruiting now
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia — Completed
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia — Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure — Stopped early
SELUTION4SFA Trial — Running, not enrolling
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes — Completed
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure — Completed
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation — Stopped early
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 — Completed
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) — Completed
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation — Stopped early
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction — Completed
A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure — Completed
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina — Completed